Inhalerx Ltd (IRX) - Total Liabilities

Latest as of December 2025: AU$2.38 Million AUD ≈ $1.69 Million USD

Based on the latest financial reports, Inhalerx Ltd (IRX) has total liabilities worth AU$2.38 Million AUD (≈ $1.69 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Inhalerx Ltd to evaluate the company's liquid asset resilience ratio.

Inhalerx Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Inhalerx Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Inhalerx Ltd.

Inhalerx Ltd Competitors by Total Liabilities

The table below lists competitors of Inhalerx Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Capitan Investment Ltd V:CAI	Canada	CA$1.24 Million
Henderson International Income Trust PLC LSE:HINT	UK	GBX40.28 Million
Anagenics Ltd AU:AN1	Australia	AU$520.80K
Decent Holding Inc Ordinary Shares NASDAQ:DXST	USA	$19.58 Million
ASIA Capital Group Public Company Limited BK:ACAP	Thailand	฿1.94 Billion
Sultan Resources Ltd AU:SLZ	Australia	AU$118.95K
ScandiDos AB ST:SDOS	Sweden	Skr24.31 Million
Sulliden Minerals SA TO:SMC	Canada	CA$2.72 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Inhalerx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See IRX net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.58	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.03	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.97	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Inhalerx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Inhalerx Ltd (2016–2025)

The table below shows the annual total liabilities of Inhalerx Ltd from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	AU$2.38 Million ≈ $1.69 Million	+206.96%
2024-12-31	AU$776.37K ≈ $549.33K	-14.82%
2023-12-31	AU$911.41K ≈ $644.88K	+156.51%
2022-12-31	AU$355.32K ≈ $251.41K	+40.25%
2021-12-31	AU$253.34K ≈ $179.26K	-56.33%
2020-12-31	AU$580.10K ≈ $410.46K	+104.53%
2019-12-31	AU$283.63K ≈ $200.69K	-30.54%
2018-12-31	AU$408.33K ≈ $288.92K	-29.54%
2017-12-31	AU$579.51K ≈ $410.04K	-53.54%
2016-12-31	AU$1.25 Million ≈ $882.59K	--

About Inhalerx Ltd

AU:IRX Australia Biotechnology

Market Cap

$4.18 Million

AU$5.91 Million AUD

Market Cap Rank

#29021 Global

#1593 in Australia

Share Price

AU$0.02

Change (1 day)

+4.35%

52-Week Range

AU$0.02 - AU$0.04

All Time High

AU$0.39